Protocol: CDISCPILOT01                                                                  Page  1 of 1 
Population: Efficacy 
Table 14-3.13 
CIBIC+ - Categorical Analysis - LOCF 
 
 
[1] Overall comparison of treatments using CMH test (Pearson Chi-Square), controlling for site group. 
Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rtf_eff_cat.sas               21:06 Monday, June 26, 2006 
 
Assessment 
 Placebo 
 (N=79)  
Xanomeline 
 Low Dose 
  (N=81)  
Xanomeline 
High Dose 
  (N=74)  
p-value 
  [1] 
 
Week 8  
n                    
 77 
 81 
 73 
0.2727 
 
Marked improvement   
  0 
  0 
  0 
 
 
Moderate improvement 
  1 (  1%)   2 (  2%)   1 (  1%) 
 
 
Minimal improvement  
 19 ( 25%)  16 ( 20%)  13 ( 18%) 
 
 
No Change            
 45 ( 58%)  48 ( 59%)  38 ( 52%) 
 
 
Minimal worsening    
 10 ( 13%)  14 ( 17%)  20 ( 27%) 
 
 
Moderate worsening   
  2 (  3%)   1 (  1%)   1 (  1%) 
 
 
Marked worsening     
  0 
  0 
  0 
 
 
Week 16 
n                    
 79 
 81 
 74 
0.4003 
 
Marked improvement   
  0 
  0 
  0 
 
 
Moderate improvement 
  0 
  3 (  4%)   2 (  3%) 
 
 
Minimal improvement  
 12 ( 15%)  12 ( 15%)  13 ( 18%) 
 
 
No Change            
 41 ( 52%)  46 ( 57%)  39 ( 53%) 
 
 
Minimal worsening    
 25 ( 32%)  19 ( 23%)  20 ( 27%) 
 
 
Moderate worsening   
  1 (  1%)   1 (  1%)   0 
 
 
Marked worsening     
  0 
  0 
  0 
 
 
Week 24 
n                    
 79 
 81 
 74 
0.6180 
 
Marked improvement   
  0 
  0 
  0 
 
 
Moderate improvement 
  1 (  1%)   1 (  1%)   0 
 
 
Minimal improvement  
  9 ( 11%)  14 ( 17%)  11 ( 15%) 
 
 
No Change            
 38 ( 48%)  37 ( 46%)  33 ( 45%) 
 
 
Minimal worsening    
 28 ( 35%)  27 ( 33%)  25 ( 34%) 
 
 
Moderate worsening   
  3 (  4%)   2 (  2%)   5 (  7%) 
 
 
Marked worsening     
  0 
  0 
  0 
 
 
